drugset / Trial / NCT04493931

Drug-drug Interaction Study of Gepotidacin

NCT04493931

Phase 1 Completed 64 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is a drug-drug interaction (DDI), pharmacokinetics (PK), safety and tolerability study in adult healthy participants, including Japanese cohort. This study is designed to assess co-administration of probe substrates with gepotidacin in study cohorts 1 to 3 and establishing PK and safety in Japanese participants in cohort 4. Food effect will also be evaluated in cohort 4.

Timeline

Start
2020-08-14
Primary completion
2020-12-21
Completion
2020-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cimetidine Small molecule 400 mg Oral
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject Gepotidacin Small molecule 1500 mg Oral
Subject Gepotidacin Small molecule 3000 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Rifampin Small molecule 600 mg Oral